Patient-care related overtones and the interplay between payers, providers, patients, governments and producers have made Life Sciences and Healthcare a complex system. But what simplifies it is the Real World Data as this can help pharma and biotech companies mine trends in real world product usage and align their marketing, market access, medical affairs and commercial operations to maximize patient benefit and revenues. In this blog, Saama’s Rajeev Gangal explains how Line of Therapy analytics can help the Life Sciences industry position the drugs better in the market and thus reach larger patient pool and maximize RoI.

With changing healthcare paradigms and stringent regulations, what remains constant, is the way we perceive diseases, and that is, as an enemy waging short-intense (Infections) or perennial (chronic) battles.  It’s perhaps thus natural to think of treatments in terms of Lines of Attack or Defense and to contain or manage the enemy or defeat it as in “the war on cancer”.

Hitherto, the physicians tried older therapies first and then moved on to the newer drugs, mostly to prevent emergence of resistance, and also prescribe drugs that were economically viable.  It’s obviously desirable that a drug, highly efficacious with the least side-effects, useful for most patients and cost effective, be tried first. This is where Line of Therapy comes to picture.